Business · 02/09/2026

National Institute of Diabetes and Digestive and Kidney Diseases to Grant Exclusive Patent License to Nulyn Science for Mifepristone and Analogues to Treat Insulin Resistance Disorders

The National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health, Department of Health and Human Services, is considering granting an exclusive patent license to Nulyn Science, a French company, to develop and commercialize mifepristone and its analogues for treating insulin resistance disorders related to hypercortisolism.